OBJECTIVES:
To evaluate total annual all-cause costs of chronic constipation (CC) among patients with different health plan benefit designs and assess incremental costs of CC in a commercially insured population. METHODS: Patients were identified from the HealthCore Integrated Research Database as follows: (1) age ≥18 years as of January 1, 2010; (2) continuous eligibility in 2010; (3) ≥2 constipation diagnoses (ICD-9-CM: 564.0x) occurring ≥90 days apart or ≥1 constipation diagnosis plus ≥1 constipation-related prescription occurring ≥90 days apart. A control group without irritable bowel syndrome, constipation, abdominal pain, or bloating was randomly selected using 1:1 matching on basic demographic characteristics. Patients were categorized by health plan benefit design into non-capitated health maintenance organizations (HMO), preferred provider organizations (PPO), Medicare Advantage (MA), and other benefit designs. Total all-cause health care costs included pharmacy costs and costs from medical services. Generalized linear models were used to evaluate the incremental costs attributable to CC. RESULTS: Of 14,854 CC patients and controls identified, 71.7% had PPO, 12.0% had non-capitated HMO, 10.2% had MA, and 6.1% had other benefit designs. Mean age (±SD) was 58.7 (±20.4) years; 75.4% were female. Overall, CC patients had $8,713 (P<0.001) higher unadjusted total annual all-cause health care costs versus matched controls; costs were $9,736 (P<0.001) higher for non-capitated HMO, $8,029 (P<0.001) for PPO, and $11,813 (P<0.001) for MA. Medical costs were the primary driver of unadjusted all-cause costs regardless of benefit design (82%-84% of total costs). This finding remained consistent in the overall study population even after adjusting for demographics and comorbidities. Total incremental all-cause costs associated with CC were $3,508 (P<0.001), with 81% for medical services. CONCLUSIONS: The economic burden of CC is substantial in a US commercially insured population. A consistent burden was seen across different health plan benefit designs, with costs driven by the use of medical services.
PGI10 ECONOMIC BURDEN ASSOCIATED WITH ULCERATIVE COLITIS IN CANADA: AN ANALYSIS USING THE RAMQ DATABASE
Lachaine J 1 , Beauchemin C 1 , Lambert-Obry V 1 , Chiva-Razavi S 2 1 University of Montreal, Montreal, QC, Canada, 2 Abbvie, QC, Canada OBJECTIVES: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that results from chronic inflammation restricted to all or part of the colon and begins in the rectum. UC significantly impact quality of life and accounts for substantial costs to the health care system and society. The objective of this study was to describe and estimate health care resource utilization in the treatment of UC from a health care system perspective. METHODS: A retrospective study of the Quebec provincial drug reimbursement program (RAMQ) was conducted using a randomly selected group of patients who received at least one diagnosis of UC (ICD-9=556.x) between January 1st, 2010 and December 31st, 2011, but who did not received a diagnosis of Crohn's disease (ICD-9=555.x). A control group of patients without any diagnosis of UC was created on a 1:1 ratio and matched for age and gender. The difference between the costs of resources consumed during the 2year study period by the two groups (using t-test) provided an estimate of the incremental cost associated with the management of UC. RESULTS: A total of 2,975 patients with UC were included in the study (mean age=55.5 years, 52% females). During the 2-year study period, patients had received a total of 57,264 scripts for anti-inflammatory drugs, immunosuppressors and/or anti-TNFα agents. The total cost of medical procedures, medications and hospitalizations were higher for UC patients, with an annual incremental cost per patient of CAN$370 (95%CI: 331-410), CAN$2,374 (95%CI: 2135-2613) and CAN$2,795 (95%CI: 2399-3192), respectively. The annual difference in direct costs between UC patients and controls was estimated at CAN$5,539 (95%CI: 5,036-6,043) per patient. CONCLUSIONS: The present analysis illustrates the high cost of treatments, the high frequency of hospitalizations resulting in increased hospitalization costs and the substantial economic burden, in terms of direct medical costs associated with UC. OBJECTIVES: Antiemetic is a drug that is effective against vomiting and nausea. The objective of this study is to calculate price trends for individual antiemetic and to describe the trends of utilization and spending on antiemetic drugs in the U.S. Medicaid program. METHODS: A retrospective descriptive analysis was performed using data from the Medicaid database from 1991 through second quarter 2011. We extracted the utilization and expenditure data from the national Medicaid pharmacy files collected by the Centers for Medicare & Medicaid Services. Study drugs include antihistamines (cyclizine, dimenhydrinate, buclizine), steroids (dexamethasone, methylprednisolone), dopamine antagonists (droperidol, ondansetron, granisetron, palonosetron). Total prescriptions reimbursed by Medicaid and total reimbursement cost were calculated by adding the data for each antiemetic identified by its NDC. The Annual totals of reimbursement per-prescription were calculated as annual total reimbursement divided by Annual total number of prescriptions. RESULTS: The total number of prescriptions which paid by Medicaid was increased from $339,822 in 1991 to $1.0 million in second quarter of 2011. The data shows 80% decrease in antiemetic utilization in 1999. The drug Ondansetron has increasing trends after 2006 up to about 70% in the first quarter of 2011. The price was in increasing rate until 2011. About 100% increase in the price of generic Zofran. The average of reimbursement per prescription has increased from $15.22 in 1991 to $36.90 in 2011. CONCLUSIONS: In the light of this study, more studies are needed to create antiemetic guidelines that would help to improve efficacy, increase the patients compliance, and decrease the antiemetic costs.
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